Nonprofit · EIN 13-5672224
MYASTHENIA GRAVIS FOUNDATION OF AMERICA INC
Also known as MGFA
Tax-exempt · HOUSTON, TX 77056
Financials
| Year ended | Form | Revenue | Expenses | Net income | Total assets | Liabilities | Net assets |
|---|---|---|---|---|---|---|---|
| December 31, 2025 | 990 | $7,559,812 | $7,077,785 | $482,027 | $15,271,954 | $2,190,069 | $13,081,885 |
| December 31, 2024 | 990 | $5,670,792 | $5,078,413 | $592,379 | $13,552,735 | $1,848,495 | $11,704,240 |
| December 31, 2023 | 990 | $3,555,325 | $3,580,103 | -$24,778 | $12,011,651 | $1,400,541 | $10,611,110 |
Financial details: 990 for the year ended December 31, 2025
Revenue
- Contributions, gifts and grants
- $6,346,619
- Program service revenue
- $585,239
- Investment income
- $502,584
- Net gain from sales of assets
- $34,084
- Net income from fundraising events
- $107,285
- Other revenue
- $125,370
Expenses
- Grants and similar amounts paid
- $849,999
- Compensation of officers, directors and key employees
- $719,186
- Other salaries and wages
- $1,282,781
- Salaries, compensation and benefits (total)
- $2,197,998
- Professional fundraising fees
- $0
- Legal fees
- $16,435
- Accounting fees
- $16,700
- Travel
- $309,868
- Depreciation
- $51,023
- Program services (functional)
- $5,506,368
- Management and general (functional)
- $975,170
- Fundraising (functional)
- $596,247
Balance sheet and other
- Total assets, start of year
- $13,552,735
- Total assets, end of year
- $15,271,954
- Total liabilities, end of year
- $2,190,069
- Net assets, end of year
- $13,081,885
- Land, buildings and equipment
- $106,555
- Publicly traded securities
- $12,568,901
- Net assets without donor restrictions
- $7,539,787
- Net assets with donor restrictions
- $5,542,098
- Gross receipts
- $7,684,233
- Employees
- 18
- Volunteers
- 500
- Year formed
- 1952
- State of legal domicile
- NY
From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.
Officers, directors and key employees
As listed on the 990 for the year ended December 31, 2025, highest compensation first.
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| Samantha Masterson | Chief Executive Officer Officer | 40 | $330,105 | $6,798 |
| Craig Stenger | Chief Operating Officer Officer | 40 | $193,297 | $10,672 |
| Michael Antonellis | Vice President, Global Marketing and Communication Key employee | 40 | $172,849 | $5,465 |
| Daryl Lee | National Director, Finance Highest-paid employee | 40 | $123,544 | $15,154 |
| Danielle Kerkovich | Vice President, Global Research Highest-paid employee | 40 | $128,742 | $50 |
| Genevieve Mvalo | National Director, Programs Highest-paid employee | 40 | $105,037 | $10,070 |
| Katharine Stober | National Director, Academi Highest-paid employee | 40 | $100,825 | $3,425 |
| Robert Thomas | Chair Trustee or director, Officer | 8 | $0 | $0 |
| Adrejia Boutte | Secretary Trustee or director, Officer | 8 | $0 | $0 |
| Ani Maitra | Director Trustee or director | 4 | $0 | $0 |
| Justin Stachtiaris | Treasurer and Vice Chair Trustee or director, Officer | 8 | $0 | $0 |
| Callum Schjerning | Director Trustee or director | 4 | $0 | $0 |
| Clyde Hosein | Director Trustee or director | 4 | $0 | $0 |
| Erin Harrigan | Director (beg 10/25) Trustee or director | 4 | $0 | $0 |
| Kelly Gwathmey MD | Director Trustee or director | 4 | $0 | $0 |
13 more people on this return
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| Kevin O'Connor MD | Director Trustee or director | 4 | $0 |
| Kyle Sell | Director Trustee or director | 4 | $0 |
| Paul Strumph MD | Director Trustee or director | 4 | $0 |
| Richard J Nowak MD | Director Trustee or director | 4 | $0 |
| Todd Fowler | Director (beg 12/25) Trustee or director | 4 | $0 |
| Wes Caudle | Director (beg 12/25) Trustee or director | 4 | $0 |
| Mark Willig | Director (beg 12/25) Trustee or director | 4 | $0 |
| Esther Land | Director (non-voting) Trustee or director | 0.25 | $0 |
| Marcia Lorimer | Director (non-voting) Trustee or director | 0.25 | $0 |
| Mark Kalish | Director (non-voting) Trustee or director | 0.25 | $0 |
| Sam Schuloff | Director (non-voting) Trustee or director | 0.25 | $0 |
| Susan Klinger | Director (non-voting) Trustee or director | 0.25 | $0 |
| Brian Gladden | Director (non-voting) Trustee or director | 0.25 | $0 |
990 for the year ended December 31, 2024: 25 people
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| Samantha Masterson | Chief Executive Officer Officer | 40 | $323,026 | $7,700 |
| Craig Stenger | Vice President, Operations Officer | 40 | $200,391 | $9,463 |
| Michael Antonellis | Vice President, Global Marketing Officer | 40 | $181,909 | $5,421 |
| Merideth O'Conner | AVP, Patient Engagement Highest-paid employee | 40 | $119,007 | $12,256 |
| Daryl Lee | National Director, Finance Highest-paid employee | 40 | $124,220 | $6,471 |
| Tasha Duncan | National Director, Strategic Parternships Highest-paid employee | 40 | $109,503 | $13,806 |
| Caroline Gaylor | National Senior Director of Development Highest-paid employee | 40 | $120,304 | $2,789 |
| Laura Chandler | National Director, Academic Affiars Highest-paid employee | 40 | $112,483 | $9,985 |
| Brian Gladden | Chair Trustee or director, Officer | 8 | $0 | $0 |
| Robert Thomas | Vice Chair Trustee or director, Officer | 8 | $0 | $0 |
| Adrejia Boutte | Secretary Trustee or director, Officer | 8 | $0 | $0 |
| Justin Stachtiaris | Treasurer Trustee or director, Officer | 8 | $0 | $0 |
| Ani Mitra | Director Trustee or director | 4 | $0 | $0 |
| Callum Schjerning | Director Trustee or director | 4 | $0 | $0 |
| Clyde Hosein | Director Trustee or director | 4 | $0 | $0 |
| Kelly Gwathmey MD | Director Trustee or director | 4 | $0 | $0 |
| Kevin O'Connor MD | Director Trustee or director | 4 | $0 | $0 |
| Kyle Sell | Director Trustee or director | 4 | $0 | $0 |
| Paul Strumph MD | Director Trustee or director | 4 | $0 | $0 |
| Richard J Nowak MD | Director Trustee or director | 4 | $0 | $0 |
| Esther Land | Director (non-voting) Trustee or director | 4 | $0 | $0 |
| Marcia Lorimer | Director (non-voting) Trustee or director | 4 | $0 | $0 |
| Mark Kalish | Director (non-voting) Trustee or director | 4 | $0 | $0 |
| Sam Schuloff | Director (non-voting) Trustee or director | 4 | $0 | $0 |
| Susan Klinger | Director (non-voting) Trustee or director | 4 | $0 | $0 |
990 for the year ended December 31, 2023: 26 people
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| Samantha Masterson | Chief Executive Officer Officer | 40 | $273,575 | $4,356 |
| Craig Stenger | Vice President, Operations Highest-paid employee | 40 | $167,312 | $4,903 |
| Michael Antonellis | Vice President, Global Mar Highest-paid employee | 40 | $158,122 | $2,624 |
| Wendi Huff | Vice President, Global Ind Highest-paid employee | 40 | $113,764 | $168 |
| Caroline Gaylor | National Director, Strateg Highest-paid employee | 40 | $109,198 | $1,575 |
| Merideth O'Conner | AVP, Patient Engagement Highest-paid employee | 40 | $106,959 | $3,385 |
| Dova Levin | National Senior Director, Highest-paid employee | 40 | $105,074 | $1,828 |
| Daryl Lee | National Director, Finance Highest-paid employee | 40 | $103,699 | $1,807 |
| Brian Gladden | Chair Trustee or director, Officer | 8 | $0 | $0 |
| Robert Thomas | Vice Chair Trustee or director, Officer | 8 | $0 | $0 |
| William Sauerwine | Vice Chair (ended 11/2023) Trustee or director, Officer | 8 | $0 | $0 |
| Adrejia Boutte | Secretary Trustee or director, Officer | 8 | $0 | $0 |
| Justin Stachtiaris | Treasurer Trustee or director, Officer | 8 | $0 | $0 |
| Kelly Gwathmey MD | Director Trustee or director | 4 | $0 | $0 |
| Richard J Nowak MD | Director Trustee or director | 4 | $0 | $0 |
| Kevin O'Connor MD | Director Trustee or director | 4 | $0 | $0 |
| Sangeeta Sawhney MD | Director Trustee or director | 4 | $0 | $0 |
| Callum Schjerning | Director Trustee or director | 4 | $0 | $0 |
| Kyle Sell | Director Trustee or director | 4 | $0 | $0 |
| Paul Strumph MD | Director Trustee or director | 4 | $0 | $0 |
| Jeffrey Pilgrim | Director (ended 4/2023) Trustee or director | 4 | $0 | $0 |
| Esther Land | Director (non-voting) Trustee or director | 4 | $0 | $0 |
| Marcia Lorimer | Director (non-voting) Trustee or director | 4 | $0 | $0 |
| Mark Kalish | Director (non-voting) Trustee or director | 4 | $0 | $0 |
| Susan Klinger | Director (non-voting) Trustee or director | 4 | $0 | $0 |
| Sam Schuloff | Director (non-voting) Trustee or director | 4 | $0 | $0 |
Address and contacts
- Address (IRS master file)
- 1 RIVERWAY STE 1700, HOUSTON, TX 77056-1997
- Mailing address (990-N for 2013)
- 355 Lexington Avenue 15th Floor, New York NY 10017
- Principal officer (990 for 2025)
- Justin Stachtiaris, 290 Turnpike Rd 5-315, Westborough, MA 01581
- Principal officer (990-N for 2013)
- Tor Holtan, 355 Lexington Avenue 15th Floor, New York NY 10017
- Signed the 990
- Justin Stachtiaris, Treasurer
- Phone
- (949) 307-3330
- Website
- www.myasthenia.org
- Return prepared by
- DESMOND & AHERN LTD
Mission
Committed to finding a cure for myasthenia gravis and closely related disorders, improving treatment options, and providing information and support to people with myasthenia gravis through research, education, community programs and advocacy.
Program accomplishments
- Evaluating, Funding, and Disseminating Critical Research: MGFA supports high-impact myasthenia gravis research at leading universities and medical institutions, often collaborating with strategic partners such as the American Brain Foundation and MGNet. Through these partnerships, it helps attract new researchers to the field by funding fellowships, pilot grants, and specialized research projects.The organization also maintains the only global MG patient registry, which has grown to nearly 3,500 participants, providing valuable data to advance research. MGFA hosts an annual scientific session in partnership with AANEM, drawing more than 250 attendees, and organizes an International Conference every three years that brings together leading MG researchers worldwide, with attendance reaching around 660 participants.In addition, MGFA keeps a broad audience of over 40,000 constituents informed about research initiatives and progress, ensuring the community stays connected to the latest developments in MG science.Expenses $5,506,368 · grants $849,999 · revenue $603,324
- Awareness and Advocacy: MGFA offers a wide range of free educational brochures, available in multiple languages, covering topics important to individuals living with myasthenia gravis, and makes them accessible to both patients and the general public. It also provides a professional manual and other key educational resources tailored for healthcare providers.In addition, MGFA leads an annual awareness campaign each June for MG Awareness Month, engaging its network of support groups and equipping individuals with toolkits, press materials, posters, and social media resources to help raise awareness of myasthenia gravis within their communities. MGFA also hosted a Patient Advocacy Organization Summit that brought together 44 representatives from 17 countries, highlighting its global commitment to collaboration and advancing support for the MG community.
- Information, Education and Support: The Myasthenia Gravis Foundation of America (MGFA) delivers broad support for people living with myasthenia gravis and their caregivers through education, community programs, and direct services. It provides accessible information, referrals, and structured support through a nationwide network of about 43 support groups, its Partners in MG Care program, and other affiliated networks. Its website serves as a central, trusted hub for up-to-date educational content, news, and disease management resources.MGFA organizes a wide range of interactive learning opportunities, including nearly 20 wellness and research webinars and 14 Community Health Fairs across the U.S. and Canada. These events allow patients and caregivers to connect with medical experts, learn about the latest research and treatments, and engage with industry leaders. The organization's annual National Patient Conference is a key gathering for the MG community, featuring research updates, patient experiences, and in-depth educational sessions designed to help individuals better manage their condition.Beyond education, MGFA fosters community engagement and awareness through platforms like Facebook and provides personalized support via its Patient Helpline, where licensed counselors assist individuals navigating the challenges of MG. It also convenes an annual Stakeholder Roundtable that brings together patients, healthcare professionals, and industry representatives to identify and address critical unmet needs. One major outcome of this collaboration is the Myasthenia Gravis Lexicon, a tool designed to improve communication between patients and healthcare providers.In addition to these ongoing efforts, MGFA also develops targeted support initiatives, such as a food insecurity program which was piloted this year that provided assistance to families during the holiday season, reflecting its broader commitment to addressing both medical and quality-of-life challenges faced by the MG community.
What it must file and when
IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.
| Tax year | Year ended | Due | IRS public records |
|---|---|---|---|
| 2025 | December 31, 2025 | May 15, 2026 | 990 on file |
| 2024 | December 31, 2024 | May 15, 2025 | 990 on file |
| 2023 | December 31, 2023 | May 15, 2024 | 990 on file |
IRS record
- EIN
- 13-5672224
- Tax-exempt status
- 501(c)(3): Charitable, religious, educational or scientific organization
- Foundation status
- Publicly supported organization (170(b)(1)(A)(vi))
- Donations deductible (Pub 78)
- Group exemption
- Exempt since
- 1954
- Accounting year ends
- December
- Files
- Form 990 or 990-EZ
- Category (NTEE)
- Medical research (H56Z)
- Group exemption
- 1322
- Assets (IRS master file)
- $15,271,954
- Income (IRS master file)
- $7,684,233
Filing history
| Form | Year ended | Revenue | Expenses | Assets | Return |
|---|---|---|---|---|---|
| 990 | December 2025 | $7,559,812 | $7,077,785 | $15,271,954 | IRS |
| 990 | December 2024 | $5,670,792 | $5,078,413 | $13,552,735 | IRS |
| 990 | December 2023 | $3,555,325 | $3,580,103 | $12,011,651 | XML |
| 990 | December 2022 | $4,388,529 | $3,790,735 | $11,363,951 | IRS |
| 990 | December 2021 | $3,840,681 | $3,008,153 | $12,076,757 | IRS |
| 990 | December 2020 | – | – | – | IRS |
| 990 | December 2018 | – | – | – | IRS |
| 990-N for 2013 Officer: Tor Holtan | December 31, 2013 | ≤ $50,000 receipts | – | – | e-Postcard |
990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 13-5672224).
Questions about MYASTHENIA GRAVIS FOUNDATION OF AMERICA INC
- What is the EIN of MYASTHENIA GRAVIS FOUNDATION OF AMERICA INC?
- The employer identification number (EIN) of MYASTHENIA GRAVIS FOUNDATION OF AMERICA INC is 13-5672224.
- Is MYASTHENIA GRAVIS FOUNDATION OF AMERICA INC tax-exempt?
- Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 1954.
- Are donations to MYASTHENIA GRAVIS FOUNDATION OF AMERICA INC tax-deductible?
- Yes. It is listed in IRS Publication 78 (Group exemption).
- Which annual return does MYASTHENIA GRAVIS FOUNDATION OF AMERICA INC file?
- Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
- When is the next return of MYASTHENIA GRAVIS FOUNDATION OF AMERICA INC due?
- The return for tax year 2026 (the year ending December 31, 2026) is due May 17, 2027. Form 8868 extends it by six months; the 990-N cannot be extended.
- When did MYASTHENIA GRAVIS FOUNDATION OF AMERICA INC last file with the IRS?
- The latest return in the IRS public files is the 990 for the year ended December 2025.
- Who is the principal officer of MYASTHENIA GRAVIS FOUNDATION OF AMERICA INC?
- The 990 for the year ended December 31, 2025 names Justin Stachtiaris.
- Who are the officers and directors of MYASTHENIA GRAVIS FOUNDATION OF AMERICA INC?
- The 990 for the year ended December 31, 2025 lists 28 people; 7 received compensation from the organization, the highest $330,105 (Samantha Masterson, Chief Executive Officer).
- How much revenue does MYASTHENIA GRAVIS FOUNDATION OF AMERICA INC have?
- On its 990 for the year ended December 31, 2025 it reported revenue of $7,559,812, expenses of $7,077,785 and total assets of $15,271,954 at year end.
Other nonprofits in HOUSTON
- LEDUCQ FOUNDATION FOR CARDIOVASCULAR RESEARCH EIN 45-4696263 · last filed 990-PF for 2024
- TEXAS HEART INSTITUTE EIN 74-6053200 · last filed 990 for 2024
- HOUSTON REGIONAL HIV AIDS RESOURCE GROUP INC EIN 76-0414232 · last filed 990 for 2021
- CLAYTON FOUNDATION FOR RESEARCH EIN 74-1541767 · last filed 990 for 2024
- RETINA RESEARCH FOUNDATION PERMANENT ENDOWMENT FUND EIN 74-1860430 · last filed 990 for 2024
- SIUT NORTH AMERICA INC EIN 76-0656947 · last filed 990 for 2024
- CLL GLOBAL RESEARCH FOUNDATION EIN 88-0517430 · last filed 990 for 2025
- RETINA RESEARCH FOUNDATION EIN 23-7087830 · last filed 990 for 2024